FDA Expands Use of Dapagliflozin to Broader Range of HF FDA Expands Use of Dapagliflozin to Broader Range of HF
The SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 9, 2023 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Is Dapagliflozin a Cardiac Anti-Aging Drug? Is Dapagliflozin a Cardiac Anti-Aging Drug?
A new study elucidates the mechanisms behind the beneficial effects of dapagliflozin in the cardiovascular system. Might it have an anti-aging effect?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dapagliflozin's HFpEF Benefit Tied to Lower Filling Pressure Dapagliflozin's HFpEF Benefit Tied to Lower Filling Pressure
Patients with HFpEF who took dapagliflozin significantly cut their pulmonary capillary wedge pressures, a likely mechanism of benefit.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 23, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Biomarkers Linked to Elevated T2D MACE Risk Biomarkers Linked to Elevated T2D MACE Risk
A secondary DECLARE-TIMI 58 trial analysis linked two biomarkers to higher cardiovascular risks in diabetes and found a strong benefit of dapagliflozin.MDedge News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 8, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Dapagliflozin Gets Expanded Heart Failure Indication in Europe Dapagliflozin Gets Expanded Heart Failure Indication in Europe
The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 9, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
DELIVER Subanalysis'Seals Deal' for Dapagliflozin in HF DELIVER Subanalysis'Seals Deal' for Dapagliflozin in HF
An analysis of the large global DELIVER trial found that dapagliflozin improved outcomes and symptoms across a wide range of patients with heart failure.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 19, 2022 Category: Internal Medicine Tags: Cardiology News Source Type: news
Dapagliflozin Reduces Hospitalizations in Patients With CKD Dapagliflozin Reduces Hospitalizations in Patients With CKD
Dapagliflozin reduced hospitalization for patients with CKD, a new study found, suggesting that dapagliflozin should be considered for treatment of these patients.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 7, 2022 Category: Endocrinology Tags: Internal Medicine News Source Type: news
Dapagliflozin Reduces Hospitalizations Among Patients With CKD
Reduction seen in rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, neoplasms (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 6, 2022 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Internal Medicine, Nephrology, Oncology, Pharmacy, Urology, Journal, Source Type: news
Dapagliflozin Reduces Hospitalizations Among Patients With CKD
TUESDAY, Dec. 6, 2022 -- For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.
Meir Schechter, M.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2022 Category: Pharmaceuticals Source Type: news
Benefits of Dapagliflozin in Heart Failure Similar for Men, Women
WEDNESDAY, Nov. 16, 2022 -- Dapagliflozin is similarly beneficial for women and men with heart failure, according to a study published online Nov. 7 in Circulation.
Xiaowen Wang, M.D., from Harvard Medical School in Boston, and colleagues examined... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2022 Category: Pharmaceuticals Source Type: news
New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease
Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
Effects of Dapagliflozin and Exenatide in T2D Effects of Dapagliflozin and Exenatide in T2D
A new study provides insight into the weight-lowering mechanisms of dapagliflozin and exenatide in obese patients with type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Dapagliflozin May Be Cost-Effective for Treating CKD
FRIDAY, Nov. 4, 2022 -- Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 4, 2022 Category: Pharmaceuticals Source Type: news
Glenmark Pharma launches drug for diabetic patients with comorbidities
The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added. Glenmark said Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg per day. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news
Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with HF might present a hazard to those with a low systolic BP, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
